Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Raymond James: 'The topline numbers presented by Black Diamond today indicate that the company has a viable asset in our view'
May 22, 2026 9:38 AM EDTRaymond James analyst Sean McCutcheon reiterated an Outperform rating and $11.00 price target on Black Diamond Therapeutics (NASDAQ: BDTX).
The analyst comments "Thursday, after market close, ASCO 2026 regular abstracts were released, and in conjunction Black Diamond reported the topline result for the longer-term follow-up from their Phase 2... More
Stifel Defending Black Diamond Therapeutics (BDTX): 'we believe investors are underappreciating the breadth of mutation silevertinib is showing'
May 22, 2026 9:37 AM EDTStifel analyst Laura Prendergast reiterated a Buy rating and $8.00 price target on Black Diamond Therapeutics (NASDAQ: BDTX).
The analyst comments "We view the preliminary median PFS of 15.2 months as highly encouraging and perhaps practice changing - the DoR had not yet been reached. 44% of patients are progression free/still on drug with median follow up ~9.8 months, suggesting PFS could increase with longer follow up. What stands out to us the most is: The breadth of mutations seen in patients who are progression free for 1 year (10 unique mutations across 8 patients). The lack of any CNS... More
